In light of the need for more selective anticancer therapy, much work has been directed at developing compounds or biological agents that target functions specific to cancer cells. To this end, numerous viruses have been engineered to exploit the dependence of cancer cells on particular anomalies that contribute to their rogue proliferative activity, such as dysfunctional p53, overactive mitogenic signaling, or a defective interferon response. The oncolytic human adenovirus dl1520 (ONYX-015) was engineered to propagate specifically in p53-deficient tumors, which comprise over half of all tumors. Based on successes in clinical trials, the full potential of dl1520 and other oncolytic viruses may be even better realized by using them in combination with conventional chemotherapy drugs.
As a model system in which to test this potential, representative cell lines from 2 common cancer types, oral squamous cell carcinoma (HN-5a) and colon adenocarcinoma (HT-29), were chosen, as well as platinum-drug-resistant variants of each.
Following preliminary screening of virus and drug combinations, dl1520 and melphalan were found to synergistically inhibit proliferation of all the cancer cell lines. Melphalan pretreatment or cotreatment with dl1520 enhanced inhibition of proliferation by dl1520 by up to 60% and increased apoptosis by up to 25%. The tight-junction protein CAR (coxsackie and adenovirus receptor), via which adenovirus enters cells, was not upregulated by treatment with melphalan, suggesting that other mechanisms contribute to synergy.
The synergy between melphalan and dl1520 suggests that tumor-selective cell killing by oncolytic viruses may be augmented by combining with cytotoxic drugs.
Tumori 2016; 102(1): 31 - 39
Article Type: ORIGINAL RESEARCH ARTICLE
AuthorsPeter J. Ferguson, Alexander Sykelyk, Rene Figueredo, James Koropatnick
- • Accepted on 04/09/2015
- • Available online on 30/09/2015
- • Published in print on 04/02/2016
This article is available as full text PDF.
- Ferguson, Peter J. [PubMed] [Google Scholar] 1, 4, * Corresponding Author (firstname.lastname@example.org)
- Sykelyk, Alexander [PubMed] [Google Scholar] 2
- Figueredo, Rene [PubMed] [Google Scholar] 1
- Koropatnick, James [PubMed] [Google Scholar] 1, 4
Department of Oncology, University of Western Ontario, London - Canada
Department of Physiology & Pharmacology, University of Western Ontario, London - Canada
Department of Microbiology & Immunology, University of Western Ontario, London - Canada
Lawson Health Research Institute, London Health Sciences Centre, London - Canada